U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07196579) titled 'Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors' on July 22.
Brief Summary: This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Cancer
Intervention:
DRUG: KXV01 TCR Lentinvivo Injection
KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reac...